• PDF: Delivered by email usually within 48 UK business hours.

Exelon (Alzheimer's Disease) - Forecast and Market Analysis to 2022

  • Publication Date:September 2013
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:62
  • ISBN:1853451

Exelon (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Exelon (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Exelon (Alzheimer's Disease) - Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer's Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Exelon (rivastigmine, rivastigmine tartrate), which is manufactured and marketed by Novartis, is a reversible ChEI indicated for the treatment of mild to moderate dementia of the Alzheimer's type. The exact mechanism of action (MOA) of rivastigmine is unknown, but it is thought to increase ACh concentrations through reversible inhibition of AChE by hydrolysis.

Scope

- Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Exelon including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Exelon for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, China and India.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for AD
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Exelon performance
- Obtain sales forecast for Exelon from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, China and India)
Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 15
3.2 Symptoms 27
4 Disease Management 29
4.1 Diagnosis 29
4.1.1 Probable Alzheimer's Disease Dementia 30
4.1.2 Possible AD Dementia 31
4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 31
4.1.4 Possible Alzheimer's Dementia with Evidence of the Alzheimer's Disease Pathophysiological Process 32
4.1.5 Preclinical AD 32
4.1.6 Mild Cognitive Impairment 33
4.2 Treatment Overview 35
5 Competitive Assessment 38
5.1 Overview 38
5.2 Strategic Competitor Assessment 38
6 Exelon (rivastigmine, rivastigmine tartrate) 41
6.1 Overview 41
6.2 Efficacy 42
6.3 Safety 43
6.4 SWOT Analysis 45
6.5 Forecast 45
7 Appendix 47
7.1 Bibliography 47
7.2 Abbreviations 52
7.3 Methodology 55
7.4 Forecasting Methodology 55
7.4.1 Diagnosed AD patients 55
7.4.2 Percent Drug-treated Patients 57
7.4.3 General Pricing Assumptions 57
7.4.4 Individual Drug Assumptions 58
7.4.5 Generic Erosion 58
7.5 Physicians and Specialists Included in this Study 59
7.6 About the Authors 60
7.6.1 Author 60
7.6.2 Global Head of Healthcare 60
7.7 About GlobalData 61
7.8 Disclaimer 61



List of Tables

Table 1: Symptoms of AD 28
Table 2: Guidelines for the Treatment of AD 35
Table 3: Most Prescribed Drugs for AD by Class in the Global Markets, 2012 36
Table 4: Leading Branded Treatments for AD, 2013 39
Table 5: Product Profile- Exelon 42
Table 6: Exelon SWOT Analysis, 2012 45
Table 7: Global Sales Forecasts ($m) for Exelon, 2012-2022 46



List of Figures

Figure 1: Atrophy of the Brain in AD 17
Figure 2: Key Pathological Features in AD Versus a Healthy Neuron 19
Figure 3: Non-Amyloidogenic Metabolism of APP 21
Figure 4: Amyloidogenic Metabolism of APP 22
Figure 5: Neurofibrillary Tangles 24
Figure 6: Oxidative Damage Due to Free Radicals 26
Figure 7: Strategic Competitor Assessment of the Marketed Products in AD, 2013 40
+44 20 8816 8548

Ask a question about Exelon (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Enter the characters you see in the picture below
Captcha